Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc. (ADIL)
Filing Type: Form 8-K (Current Report)
Date of Report: November 25, 2025
Event: Entry into a Material Definitive Agreement (Warrant Inducement Transaction)
Key Financial Metrics
- Gross Proceeds: Approximately $2.86 million received from the exercise of existing warrants.
- Transaction Costs: Financial advisory fee of 8.0% of gross proceeds plus $25,000 in legal fees payable to A.G.P./Alliance Global Partners.
- Shares Issued: 9,215,675 shares of Common Stock issued upon exercise of Series C-1 and Series E Warrants.
- Exercise Price: Reduced to $0.31 per share for the existing warrants.
- New Securities Issued: 13,823,512 Series F Warrants issued as inducement.
- Use of Proceeds: Working capital and general corporate purposes.
Note: This filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes and Transaction Details
The Company entered into an Inducement Agreement with a holder of Series C-1 and Series E Warrants. Key terms include:
- Exercise of Existing Warrants: The holder agreed to exercise warrants for an aggregate of 9,215,675 shares at the reduced price of $0.31 per share. The transaction closed on November 28, 2025.
- Issuance of New Warrants: In consideration for the immediate exercise, the Company issued unregistered Series F Warrants to purchase up to 13,823,512 shares.
- Lock-Up Provisions: The Company agreed not to issue Common Stock or equivalents for 60 days, with exceptions for an "at the market" (ATM) offering beginning on the 31st day. Variable Rate Transactions are restricted for six months.
- Registration: The Company must file a resale registration statement for the New Warrant Shares within 30 days and seek effectiveness within 60 days (or 90 days if reviewed).
Guidance, Outlook, and Risks
- Stockholder Approval Requirement: The New Warrants cannot be exercised until stockholder approval is obtained. The Company must hold a meeting within 120 days of the closing date to seek this approval. If not obtained, meetings must be held every 90 days thereafter.
- Warrant Terms: New Warrants have an exercise price of $0.31 per share, are exercisable 24 months from the Stockholder Approval Date, and include cashless exercise provisions if no effective registration statement is available.
- Ownership Caps: Exercise is limited if it would cause the holder to beneficially own more than 4.99% or 9.99% of outstanding shares.
- Risk Factors: The New Warrants are unregistered and cannot be sold in the U.S. absent registration or exemption. The transaction relies on the Company's ability to secure stockholder approval and maintain an effective registration statement.
Investor Verification Checklist
- Verify the status of the Resale Registration Statement for the New Warrant Shares (filing deadline: 30 days from Nov 25, 2025).
- Confirm the date and outcome of the stockholder meeting required to approve the exercise of the 13,823,512 New Warrants.
- Monitor the Company's ability to maintain an effective registration statement to allow cashless exercise of the New Warrants.
- Review the impact of the 8.0% advisory fee on the net proceeds available for working capital.
- Check for any subsequent filings regarding the "at the market" (ATM) offering permitted after the 31-day lock-up period.